Goldman Sachs initiated coverage of Geron with a Neutral rating and $3 price target. The analyst noted that Geron will submit for approval of imetelstat in LR-MDS in both the US/Europe in 2023, and assumes "a high likelihood of approval," but sees "limited potential discovery value for the agent over 2023 as the agent undergoes regulatory review." Goldman Sachs estimates the unadjusted global peak sales for imetelstat of $1.0B.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GERN:
